"Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial." G. Bermudo-Peloche, B. Del Rio, V. Vicens-Zygmunt, et al. Eur Respir J 2025; 65: 2402249.
- DOI
- 10.1183/13993003.52249-2024
- Published
- 2026 Jul
- Container
- The European respiratory journal
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 4 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1183/13993003.52249-2024,
title = {"Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial." G. Bermudo-Peloche, B. Del Rio, V. Vicens-Zygmunt, et al. Eur Respir J 2025; 65: 2402249.},
year = {2026},
journal = {The European respiratory journal},
doi = {10.1183/13993003.52249-2024},
url = {https://doi.org/10.1183/13993003.52249-2024}
}RIS
TY - JOUR TI - "Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial." G. Bermudo-Peloche, B. Del Rio, V. Vicens-Zygmunt, et al. Eur Respir J 2025; 65: 2402249. PY - 2026 JO - The European respiratory journal DO - 10.1183/13993003.52249-2024 UR - https://doi.org/10.1183/13993003.52249-2024 ER -
APA
"Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial." G. Bermudo-Peloche, B. Del Rio, V. Vicens-Zygmunt, et al. Eur Respir J 2025; 65: 2402249.. (2026). The European respiratory journal. https://doi.org/10.1183/13993003.52249-2024
Source records
- pubmed · retrieved 2026-09-27T10:58:34.343Z